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Abstract
Background: The simultaneous accumulation of different misfolded proteins in the central nervous system is a common
feature in many neurodegenerative diseases. In most cases, co-occurrence of abnormal deposited proteins is observed in
different brain regions and cell populations, but, in some instances, the proteins can be found in the same cellular
aggregates. Co-occurrence of tau and a-synuclein (a-syn) aggregates has been described in neurodegenerative disorders
with primary deposition of a-syn, such as Parkinson’s disease and dementia with Lewy bodies. Although it is known that tau
and a-syn have pathological synergistic effects on their mutual fibrillization, the underlying biological effects remain
unclear.
Methodology/Principal Findings: We used different cell models of synucleinopathy to investigate the effects of tau on a-
syn aggregation. Using confocal microscopy and FRET–based techniques we observed that tau colocalized and interacted
with a-syn aggregates. We also found that tau overexpression changed the pattern of a-syn aggregation, reducing the size
and increasing the number of aggregates. This shift was accompanied by an increase in the levels of insoluble a-syn.
Furthermore, co-transfection of tau increased secreted a-syn and cytotoxicity.
Conclusions/Significance: Our data suggest that tau enhances a-syn aggregation and toxicity and disrupts a-syn inclusion
formation. This pathological synergistic effect between tau and a-syn may amplify the deleterious process and spread the
damage in neurodegenerative diseases that show co-occurrence of both pathologies.
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Introduction
Synucleinopathies are neurodegenerative disorders character-
ized by the abnormal deposition of a-synuclein (a-syn) in
filamentous intracellular inclusions known as Lewy bodies (LBs).
The most common synucleinopathy is Parkinson’s Disease (PD),
but other neurodegenerative diseases share this pathological
feature. These include dementia with Lewy bodies (DLB) and
multiple system atrophy [1]. The discovery of mutations in the
SNCA gene, which encodes a-syn, in familial forms of PD or DLB
has provided strong evidence for a central role of a-syn in
synucleinopathies [2,3,4,5,6,7]. Further support was provided by
studies that showed that elevated levels of soluble oligomers of a-
syn can be detected in the brain homogenates of patients with PD
and DLB [8,9].
The simultaneous accumulation of different proteins in the
central nervous system (CNS) is a common feature in many
degenerative diseases. In particular, the deposition of tau and
a-syn in the CNS has been described in disorders with primary
deposition of a-syn, such as familial and sporadic PD, sporadic
DLB, and multiple system atrophy [10,11,12,13,14,15,16,17].
In DLB, tau-positive LBs are typically restricted to limbic areas
and, in most of cases, associated with Ab deposits
[11,13,14,15,16,18]. Conversely, a-syn deposition has been
identified in some patients with disorders characterized by
prominent tau pathology, such as familial and sporadic AD
[19,20,21], Down syndrome [22], progressive supranuclear
palsy [23], Parkinsonism dementia complex of Guam [24], and
frontotemporal dementia [25,26]. In these cases, colocalization
of tau and a-syn aggregates is also typically restricted to the
amygdala and other limbic areas [27]. Additional data
supporting a connection between a-syn and tau comes from
genetic studies that link the MAPT gene, which encodes tau,
with increased risk of sporadic PD [28,29,30]. Although the co-
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many neurodegenerative disorders, the functional consequenc-
es of the primary deposited protein on secondary pathology has
been investigated very little.
We have recently described a family with four affected
members with clinical features of DLB [11]. The most distinctive
clinical characteristic of this family was an age of onset in the mid
20 s. Neuropathological examination of the proband also
disclosed unusual features, in particular generalized LB pathology
and neurofibrillary tangles that colocalized in most of the affected
neurons. No amyloid deposits were detected in any brain region.
The unusual neuropathological feature in this family together
with the observation that coexistence of a-syn and tau pathologies
is common in sporadic DLB led us to hypothesize a possible
pathological synergistic effect between tau and a-syn. In order to
test this hypothesis, in the present article we investigated the
effects of tau in various neuronal cell models of a-syn
aggregation. We found that tau colocalized with a-syn aggregates
in a human cell line and primary neuronal cultures. In addition,
overexpression of tau increased the number of a-syn aggregates,
the levels of high molecular weight species of a-syn, and
enhanced a-syn toxicity.
Results
Tau colocalizes with a-syn aggregates
To test the effects of tau on a-syn aggregation we used a well-
established model in which co-transfection of a-syn (syn-T) and
synphilin1-V5 leads to a-syn aggregation [31]. This model is
based on the expression of a-syn tagged with a truncated non-
fluorescent form of GFP (syn-T). It has been previously shown
that the expression of GFP-tagged tubulin or synaptophysin does
not form aggregates [32], suggesting that a-syn is the primary
element driving aggregation in the syn-T model. H4 cells were
co-transfected with syn-T, synphilin1 and tau and immuno-
stained with antibodies against tau and a-syn. We observed that
tau colocalized with a-syn in some but not all aggregates using
confocal microscopy (Fig. 1A). As a control, we co-transfected H4
cells with syn-T, synphilin1 and mCherry-tubulin and we did not
observe colocalization of a-syn aggregates with tubulin (Fig. S1).
Since colocalization has a spatial resolution of .250 nm, we used
fluorescence lifetime imaging microscopy (FLIM) to test whether
tau and a-syn interact more closely. FLIM is a Fo ¨rster resonance
energy transfer (FRET)-based assay that relies on the principle
that when two specific fluorophores are in close proximity
(,10 nm), the measured fluorescence lifetime of the donor
fluorophore is shortened in proportion to the distance between
the fluorophores [33,34]. In our a-syn inclusion model, we
double immunostained with antibodies against a-syn and tau with
Alexa Fluor 488 and 555-labeled antibodies, respectively. The
donor fluorophore (Alexa Fluor 488, a-syn) had a fluorescence
lifetime of ,2.6 ns in the absence of a FRET acceptor. In some
aggregates, the acceptor (Alexa Fluor 555, tau) was in close
proximity to the donor, and the lifetime was shortened to
,2.2 ns. The shortening in fluorescence lifetime is represented in
the pseudocolored image by a shift towards the green-blue color
(Fig. 1A). In addition, phosphorylated tau also colocalized with a-
syn aggregates (Fig. 1B).
The interaction between tau and a-syn was further confirmed in
primary cultured neurons. It has been previously shown that
overexpression of a-syn-GFP in hippocampal neurons generates a-
syn aggregates [32]. Mouse primary cortical neurons were
transfected with a-syn-GFP and tau-RFP and their colocalization
was assessed by confocal microscopy. Tau and a-syn colocalized
not only in aggregates but also in other parts of the cell (Fig. 2).
The interaction was also confirmed using FLIM. A clear decrease
in Alexa Fluor 488 lifetime was detected in neurons transfected
with a-syn and tau when compared to neurons transfected only
with a-syn. The lifetime shortening was particularly evident in the
aggregates (Fig. 2). Taken together, these data indicate that tau
and phosphorylated tau colocalize and interact with a-syn in
aggregates.
Overexpression of tau shifts a-syn aggregation pattern
Next, we asked whether the observed colocalization and
interaction between tau and a-syn would alter the aggregation
pattern of a-syn. Co-transfection with tau resulted in an increase in
the number of a-syn inclusions per cell and a reduction in their
size. To quantify this shift in the aggregation pattern we classified
cells in an unbiased manner into two groups: cells with less than 15
aggregates and cells with more than 15 aggregates (Fig. 3A). We
detected a ,25% increase of cells with more than 15 aggregates
when tau was co-transfected (Fig. 3B). These data suggest that tau
shifts the a-syn aggregation pattern and favours the formation of
more and smaller aggregates. To test whether the increase of
aggregates was due to redistribution of insoluble a-syn or to an
increase of total a-syn levels, we measured the levels of a-syn in the
absence or presence of tau. After quantification, we found no
difference in total syn-T levels when cells were co-transfected with
tau (Fig. 3C).
Tau increases insoluble high molecular weight (HMW)
species of a-syn and promotes secretion of a-syn
Next, we tested whether the observed increase in the
number of aggregates in the presence of tau could modify
insoluble a-syn species in our inclusion model. We analyzed
the NP40-insoluble fraction by SDS-PAGE in H4 cells co-
transfected with empty vector or tau. In cells co-transfected
with tau, there was an increase in both syn-T and synphilin1-
V5 protein levels, indicating that tau enhances the accumu-
lation of insoluble a-syn (Fig. 4A). Moreover, native PAGE of
t h eN P 4 0 - i n s o l u b l ef r a c t i o nr e v e a l e da ni n c r e a s ei nH M W
species of a-syn when tau was co-transfected (Fig. 4B). To
further confirm the enhancement of a-syn aggregation by tau,
we performed the same experiments in another cell model. By
using a protein-fragment complementation assay, it has been
shown that transfection of H4 cells with non-fluorescent
fragments of GFP fused to a-syn (GN-link-aSyn and aSyn-
GC) can generate HMW species of a-syn [35]. These HMW
species can be analyzed by either fluorescence microscopy or
by western blot, where the smear reflects a wide range of a-syn
oligomeric species [35]. Here, H4 cells stably expressing GN-
link-aSyn and aSyn-GC were transfected with either tau or an
empty vector. Native PAGE of total cell lysates was performed
and a smear indicative of HMW species of a-syn was detected.
Under these conditions, an increase in the smear was observed
in cells transfected with tau (Fig. 4C). To rule out the
possibility that the observed effects of tau on a-syn aggregation
were mediated by the presence of tagged a-syn, we repeated
our experiments using untagged a-syn. In H4 cells transfected
with wt a-syn and tau, an increase in the smear was also
observed when compared with cells transfected with wt a-syn
(Fig. 4D). These results suggest that tau enhances the
formation of insoluble HMW species of a-syn in different
neuronal cell models.
Different studies have indicated that a-syn can be secreted from
neuronal cells [36,37,38,39], suggesting a mechanism of patho-
logical propagation in synucleinopathies. We therefore asked
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26609Figure 1. Tau and phospho-tau colocalize and interact with a-syn aggregates in H4 neuroglioma cells. H4 cells were co-transfected with
syn-T plus synphilin1-V5 and empty vector or tau. A, After 48 h cells were fixed and immunostained for a-syn and tau with Alexa Fluor 488 and Alexa
555-labeled antibodies, respectively. Images were analyzed by confocal microscopy and FLIM. Tau and a-syn colocalize in some aggregates but not in
all of them (bottom panels). Fluorescence lifetime values are shown in the pseudocolored image. The closeness between a-syn and tau in some
aggregates is reflected by a shorter lifetime of Alexa Fluor 488 in the presence of tau. This is represented as a shift from red-yellow towards the green-
blue pseudocolor. B, H4 cells were fixed and immunostained for phospho-tau and a-syn with Alexa Fluor 488 and Alexa 555-conjugated antibodies,
respectively. Colocalization between phospho-tau and a-syn was observed in some aggregates.
doi:10.1371/journal.pone.0026609.g001
Figure 2. Tau colocalizes and interacts with a-syn aggregates in mouse cortical neurons. Cortical neurons were co-transfected after 7 days
in vitro with a-syn-GFP and tau-RFP. Neurons were then fixed and immunostained for a-syn and tau with Alexa Fluor 488 and Alexa Fluor 555-
conjugated antibodies, respectively. Images were analyzed by confocal microscopy and FLIM. The close proximity between a-syn and tau is reflected
by a shift towards the green-blue color. The shortening in fluorescence lifetime is particularly evident in some aggregates (arrows).
doi:10.1371/journal.pone.0026609.g002
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inclusion model. We co-transfected cells with empty vector or tau
and measured the levels of a-syn in the conditioned medium. We
found that co-transfection with tau increased the levels of secreted
a-syn by 80% (Fig. 4E).
Tau enhances a-syn toxicity
Finally, we asked whether the increase in a-syn aggregates in
the presence of tau could affect cell viability. We used the
release of adenylate kinase to the culture medium as a measure
of cytotoxicity, which has been demonstrated to be a sensitive
and consistent assay in a-syn cell models [35,40]. We observed
a significant increase in cytotoxicity in cells co-transfected with
tau compared to cells transfected with an empty vector (Fig. 5A).
These results were confirmed using the commonly used MTT
cell viability assay (Fig. 5B). Cells transfected with tau showed a
decrease in cell viability when compared to cells transfected
with an empty vector. To rule out the possibility that the
toxicity was merely due to tau overexpression, we transfected
H4 cells with tau vector in the absence of a-syn. As shown in
Fig. 5C, there was no increase in cytotoxicity under these
conditions. Taken together, these data suggest that tau
enhances a-syn cytotoxicity.
Discussion
In this study, we showed that tau colocalized and interacted
with a-syn aggregates in H4 cells and primary neuronal cultures.
This interaction is associated with more a-syn aggregates, HMW
species and enhanced toxicity. Thus our results support the notion
that tau is not simply a bystander, but rather enhances the
pathological aggregation of a-syn.
a-syn is a presynaptic protein localized mainly in axon
terminals that plays a role in synaptic function [41]. Tau is a
microtubule-associated protein localized along the axon that
stabilizes microtubules [42,43] and is involved in cellular
trafficking and axonal transport [44]. Both are highly expressed
in the CNS, are synthesized as native unfolded proteins and have
the propensity to form pathological insoluble intracellular
aggregates in the CNS in different neurodegenerative diseases.
Few studies have investigated the interaction between these two
proteins. Initial studies identified soluble tau as a ligand for a-syn
by affinity chromatography and direct binding studies [45]. a-syn
has also been shown to stimulate tau phosphorylation at different
serine residues in different cellular and animal models
[45,46,47,48]. This functional link could be relevant for many
neurodegenerative diseases in which a-syn and tau co-aggregate,
since an increase in hyperphosphorylated tau is one of the key
features in the brains of all tauopathies and has been shown to
reduce binding of tau to microtubules [49]. Other studies have
also suggested a pathological synergistic effect between a-syn and
tau. a-syn can aggregate in vitro, and this is greatly enhanced by
co-incubation with tau in a concentration-dependent manner
[14]. Interestingly, the effects were specific for tau because co-
incubation with Ab did not enhance a-syn polymerization [14].
More recently, data obtained from a novel cellular model
demonstrated that few amounts of fibrillized a-syn seeds are
able to induce intracellular massive tau aggregation [50]. These
tau aggregates were hyperphosphorylated and occupied almost all
the soma, sharing similar characteristics with neurofibrillary
tangles. These data support the idea that cross-seeding of
pathologic proteins can occur in some neurodegenerative
diseases. Transgenic animal studies also support a synergistic
effect between Ab, tau and a-syn pathologies [51]. In particular,
a transgenic mouse model that develops Ab, tau and a-syn
pathologies exhibits accelerated cognitive decline with enhance-
ment of all three pathologies. Although it is difficult to determine
whether the increase in a-syn and tau pathologies in this model is
also mediated by Ab, the results clearly support the notion that
Ab, tau and a-syn promote the aggregation of each other. In this
study, we confirm and extend these observations in various
neuronal models of synucleinopathy. The tau-induced increase in
the number of aggregates and HMW species of a-syn observed in
our study provides evidence that tau synergistically affects the
polymerization of a-syn. In particular, tau increased the levels of
insoluble syn-T rather than affecting total levels. A possible
explanation for the increase in the insoluble syn-T fraction is the
ability of tau to inhibit histone deacetylase 6 (HDAC6), a key
component of the aggresome complex [52]. This inhibitory effect
of tau on HDAC6 could affect the transport of small aggregates
Figure 3. Overexpression of tau shifts the pattern of a-syn
aggregation. H4 cells were co-transfected with syn-T plus synphilin1-
V5 and empty vector or tau. Co-transfection with tau in this model led
to an increase in the number of inclusions and a reduction in their size.
A, Cells were classified in two groups: cells with less than 15 aggregates
and cells with more than 15 aggregates. B, Co-transfection of cells with
tau increased the percentage of cells with .15 aggregates as compared
with those transfected with empty vector (n=250 cells). Results are
mean 6 SEM of 4 independent experiments. C, Total levels of syn-T
were measured by western blot. GAPDH was used as a loading control.
A representative experiment is shown (n=4 independent experiments).
doi:10.1371/journal.pone.0026609.g003
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our observation that co-expression of tau leads to smaller a-syn
inclusions and enhanced toxicity may suggest that microaggre-
gates are one of the key factors that mediate toxicity in our
model. This is consistent with studies that show a massive
presence of small aggregates in presynaptic terminals associated
with loss of dendritic spines in the brains of patients with DLB
[53]. Taken together, these results support the idea that
microaggregates, rather than LBs, likely represent the pathogenic
component that drive neurodegeneration in synucleinopathies.
The increase in a-syn HMW species in the presence of tau in our
study also provides evidence for a central role of soluble
oligomers in DLB and other synucleinopathies. It is tempting to
speculate that, in the presence of tau, these microaggregates may
drive dendritic and synaptic damage by slowly releasing
oligomeric forms of a-syn.
Different studies have identified that monomeric and
oligomeric a-syn are secreted to the extracellular medium from
neuronal cells via exocytosis [36,37,38,39]. These findings
provide strong evidence for direct cell-to-cell propagation of a-
syn, similar to that observed in prion diseases [54]. Here, we
detected an increase in a-syn secretion when tau was
overexpressed. Although we cannot completely rule out that
t h ei n c r e a s ei ne xtracellular a-syn levels in the presence of tau is
d u et om e m b r a n el e a k a g e ,t h el a r g ei n c r e a s eo b s e r v e d
compared to the slight toxicity argues against this possibility.
Instead, this suggests that a-syn secretion might be triggered by
the toxic properties of overexpressed a-syn and that tau
specifically enhances a-syn secretion. This tau-enhanced
secretion of a-syn may be relevant in cases with a co-
occurrence of a-syn and tau pathologies, such as our early-
onset DLB family [11]. Together, our data reinforce the notion
that synergistic effects between a-syn and tau may be a relevant
disease component that enhances the pathological cascade and
spreads the damage in neurodegenerative diseases that show
co-occurrence of both pathologies.
Figure 4. Tau increases insoluble a-syn, high molecular weight species and extracellular a-syn levels. H4 cells were co-transfected with
syn-T plus syphilin1-V5 and empty vector or tau. After 48 h cells were lysed and the insoluble fraction was resolved in SDS-PAGE (A) or native-PAGE
(B) gels. When tau was co-transfected, we observed an increase in the levels of insoluble a-syn and HMW species of a-syn. GAPDH was used as a
loading control. A representative experiment is shown (n=4 independent experiments). C, Stable H4 cells expressing a-syn constructs (GN-link-aSyn
and aSyn-GC) were transfected with either empty vector or tau. After 36 h, cells were lysed and the sample was run under non-denaturing conditions.
An increase in the smear was observed in cells co-transfected with tau. GAPDH was used as a loading control. A representative experiment is shown
(n=4 independent experiments). D, H4 cells were co-transfected with wt a-syn plus empty vector or tau. After 48 h, cells were lysed and the sample
was run under non-denaturing conditions. An increase of a-syn HMW species was observed in cells co-transfected with tau. GAPDH was used as a
loading control. A representative experiment is shown (n=3 independent experiments). E, H4 cells were co-transfected with syn-T plus synphilin1-V5
and either empty vector or tau. Non-transfected cells (NT) were used as a control. After 48 h, conditioned medium was collected and the levels of a-
syn in media were measured by ELISA. Levels of extracellular a-syn were higher in cells transfected with syn-T plus synphilin1-V5, and co-transfection
with tau further increased a-syn extracellular levels. Data are mean 6 SEM of 4 independent experiments performed in duplicate. * p,0.05 compared
to empty vector.
doi:10.1371/journal.pone.0026609.g004
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Plasmids, Cell lines and Transfections
A construct encoding for the human wild-type a-syn with a C-
terminal tag corresponding to a truncated fragment of GFP
(referred to as syn-T) was used in combination with a construct
encoding synphilin1 (tagged with a V5 tag) as a model of a-syn
aggregation [31,32]. Alternatively, constructs encoding for the
human wild-type untagged or GFP-tagged a-syn were used alone
[31]. The construct encoding for the longest isoform (2N4R) of
human wild-type tau (referred to as tau) was a kind gift from Jesus
Avila (Centro de Biologı ´a Molecular, Madrid, Spain), and the
construct encoding for the human wild-type tau tagged with RFP
was a kind gift from Rohan de Silva (UCL Institute of Neurology,
London, UK). Where indicated, cells were co-transfected with a
construct encoding for a-tubulin tagged with mCherry. The
plasmid was a kind gift from Domingos Henrique (Instituto de
Medicina Molecular, Lisbon, Portugal).
Human neuroglioma (H4) cells and primary neuronal cultures
were used in this work. H4 cells were maintained in OPTI-MEM
with 10% FBS at 37uC and plated onto four-well chamber slides
(Labtek, Nalge-Nunc, Naperville, IL, USA) or 10 cm dishes 24 h
prior to transfection. H4 cells were transfected with equimolar
amounts of the constructs encoding syn-T and synphilin1-V5 and
either empty vector or a construct encoding for tau. The percentage
of cells transfected with the three plasmids was ,5–10%. H4 cells
stably expressing GN-link-aSyn and aSyn-GC were transfected
with either empty vector or a construct encoding for tau.
Mouse cortical neurons were prepared as previously described
[33]. Neurons were cultured in Neurobasal medium containing
B27 supplement (Invitrogen, Carlsbad, CA, USA). After 7 days in
vitro, cells were transfected with a-syn-GFP and tau-RFP
constructs and immunostained.
H4 cells and mouse cortical neurons were transiently transfected
with Fugene 6 (Roche Diagnostics, Mannheim, Germany) and
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) reagents,
respectively, according to the manufacturer’s instructions.
Cytotoxicity Assays
Cells were plated onto 6-well plates at 200.000 cells/ml density
24h before transfection. Conditioned medium was collected 48 h
after transfection, centrifuged at 10000xg at 4uC for 5 min to
remove cells in suspension, and the activity of adenylate kinase was
measured using ToxiLight
TM (Cambrex, Walkersville, MD, USA),
according to the manufacturer’s protocol. Cell viability was also
monitored by the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay as previously described
[55]. MTT (0.5 mg/ml) was added to cultures and incubated for 2h
at 37uC. The reaction media were then aspirated and DMSO was
used to solubilize the blue formazan product prior its quantification
at 570 nm (ELx-800 Absorbance microplate reader, BioTek).
Results were expressed as the percentage of viable cells.
Immunocytochemistry and antibodies
Cells were fixed and immunostained 48 h after transfection as
described elsewhere [56]. Briefly, paraformaldehyde-fixed cells
were incubated with primary antibodies overnight at 4uC. Cells
were washed three times with TBS-Tween 0.1%, and incubated
with Alexa Fluor 488- or 555-labeled secondary antibodies (1:500;
Invitrogen, Carlsbad, CA, USA) for 1 hour at room temperature.
Cells were then washed three times with TBS-Tween 0.1% and
kept at 4uC in TBS until visualization. We used the following
primary antibodies: syn-1 (1:1000, BD Transduction Labs, San
Jose, CA, USA), a-syn (1:100, Cell Signalling Technology,
Danvers, MA, USA), Tau-13 (1:200, MBL, Nagoya, Japan), Tau
HT7 (1:100, Innogenetics, Ghent, Belgium), ser396/404 phospho-
tau (PHF1, a kind gift from Peter Davies, Albert Einstein College
of Medicine, NY).
Confocal microscopy and Fluorescence Lifetime Imaging
Microscopy (FLIM)
Confocal microscopy and FLIM was performed using a Leica
inverted fluorescent confocal microscope (Leica TCD SP5-AOBS,
Wetzlar, Germany). FLIM has been described previously as a
Figure 5. Tau increases a-syn cytotoxicity. A, H4 cells were co-transfected with syn-T plus synphilin1-V5 and either empty vector or tau.
Conditioned medium was collected 48 hours after transfection, and toxicity was determined by measuring the activity of adenylate kinase. Co-
transfection of cells with tau in the a-syn inclusion model increased the levels of adenylate kinase in the medium, indicative of an increase in
cytotoxicity. Results are mean 6 SEM of 7 independent experiments performed in triplicate. *p,0.05 compared to empty vector. B, H4 cells were co-
transfected with syn-T plus synphilin1-V5 and either empty vector or tau. After 48 h cell viability was determined by MTT assay. Data are mean 6 SEM
of 3 independent experiments performed in quadruplicate. *p,0.05 compared to empty vector. C, H4 cells were transfected with empty vector or
tau. Conditioned medium was collected 48 hours after transfection, and adenylate kinase activity was determined. Transfection of tau does not
induce significant toxicity in the absence of a-syn aggregates. Results are mean 6 SEM of 5 independent experiments performed in triplicate.
*p ,0.05 compared to empty vector.
doi:10.1371/journal.pone.0026609.g005
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technique is based on the observation that fluorescence lifetimes of
a donor fluorophore shorten in the presence of a FRET acceptor
in close proximity (,10 nm). The decrease in lifetime is
proportional to the distance between the fluorophores at R
6.
The Leica SP5 confocal microscope used to perform FRET/
FLIM experiments was equipped with three pulsed lasers (405,
470, 640 nm) and time-correlated single photon counting
detectors. The hardware/software package allows the measure-
ment of fluorescence lifetimes on a pixel-by-pixel basis with high
spatial resolution. Donor fluorophore (Alexa Fluor 488) lifetimes
were fitted to two exponential decay curves as described [34,57].
For a-syn-tau FRET/FLIM experiments, cells were fixed and
double-immunostained for a-syn and tau as described above. As a
positive control, cells were immunostained against a-syn and then
incubated with equimolar concentrations of Alexa Fluor 488 and
Alexa 555-labeled secondary antibodies (Invitrogen, Carlsbad,
CA, USA; Fig. S2). All samples were compared to a negative
control in which the donor (Alexa Fluor 488) fluorescence lifetime
was measured in the absence of the acceptor (no FRET
,2500 ps).
Quantification of a-syn inclusions
Cells were analyzed by two independent observers blinded to
the experimental conditions. Ten 20x fields were assessed for each
well and two wells were assessed for each condition and
experiment. Each field contained 1–10 transfected cells and 80–
100 cells were assessed for each experiment. A total of four
independent experiments were performed for each condition.
Transfected cells were detected and scored based on the a-syn
aggregation pattern. Cells were classified into two groups: cells
with less than 15 aggregates and cells with more than 15
aggregates. Results were expressed as a percentage of the total
number of transfected cells.
Detergent-solubility fractionation
Cells were lysed in 1% NP-40 buffer and lysates were incubated
for1 houroniceandcentrifuged at15,000xgfor60 minat4uC.The
supernatant was collected and designated NP-40-soluble fraction,
and the pellet was resuspended in the same lysis buffer, sonicated
twice for 10 s and collected as the NP-40-insoluble fraction.
Western Blot
Lysate protein concentration was determined using a Bradford
protein assay. Each cell lysate (20–40 mg) was electrophoresed in 10%
Tris-glycine gels for Western blot analysis. SDS-PAGE was performed
with SDS-containing running and sample loading buffers, whereas
native-PAGE was performed with 4–15% TGX
TM gels (Biorad,
Richmond, CA, USA) using SDS-free running and sample loading
buffers. The immunoblotting was performed overnight at 4uCw i t h
the following primary antibodies: a-syn (Syn-1, 1:1,000, BD
Transduction Laboratories, San Jose, CA, USA), anti-V5 (1:1000,
Abcam, Cambridge, UK), GAPDH (1:10,000, Millipore, Bedford,
MA, USA), or Tau HT7 (1:500, Innogenetics, Ghent, Belgium). The
immunoblotting was followed by detection with a HRP-conjugated
secondary antibody and enhanced chemiluminescence substrate
(Millipore, Bedford, MA, USA) or with an infrared fluorescent-
labelled secondary antibody (IRDye, Rockland Immunochemicals,
Gilbertsville, PA). Bands on films were quantified using Odyssey
software (LI-COR, Lincoln, NE, USA).
Human soluble a-syn ELISA
Cells were plated onto 6-well plates at 200.000 cells/ml
density 24 h before transfection. Conditioned medium was
collected 48 h after transfection, centrifuged at 10000xg at 4uC
for 5 min to remove cells in suspension, and the concentration
of a-syn was quantified using an ELISA kit (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s protocol.
Briefly, samples are loaded into wells coated with a specific a-
syn monoclonal antibody. After incubation, detection a-syn
rabbit polyclonal antibody is loaded into the wells. After
washing, a HRP-conjugated anti-rabbit IgG (anti-rabbit IgG
HRP) is added. After incubation and washing, a substrate
solution is added. Absorbance is then read at 450 nm. In this
assay the intensity of this colored product is directly
proportional to the concentration of a-syn present in the
original specimen.
Statistical Analysis
Data are shown as mean 6 standard error (SEM) of at least 3
independent experiments. Statistical significance was determined
by one-way analysis of variance (ANOVA) followed by Tukey’s
multiple comparison test. The level of significance was set at 5%
(a=0.05).
Supporting Information
Figure S1 Tubulin does not colocalize with a-syn
aggregates. H4 cells were co-transfected with syn-T plus
synphilin1-V5 and mCherry-tubulin. After 48 h cells were fixed
and immunostained for a-syn with a primary and an Alexa Fluor
488-labeled secondary antibodies. Images were analyzed by
confocal microscopy and no colocalization between a-syn and
tubulin was observed.
(EPS)
Figure S2 Positive control for the FLIM assay. H4 cells
were co-transfected with syn-T and synphilin1-V5, fixed and
incubated with a primary antibody against a-syn. Cells were then
washed and incubated with equimolar concentrations of Alexa
Fluor 488 and Alexa Fluor 555-labeled secondary antibodies. As
expected, we observed wide colocalization and the donor
fluorescence lifetime was significantly shortened as reflected by
the blue pixels in the pseudocolored lifetime image. Photobleach-
ing of the FRET acceptor (square) led to an almost complete loss
of the FRET signal with an increase in the lifetime of the donor
fluorophore. This is reflected by a shift towards green in the
pseudocolored lifetime image.
(EPS)
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